{"classes":[{"categories":[{"measurements":[{"comment":"The median OS was not yet reached for either the lenvatinib or the placebo arm (including crossover participants) at data cutoff date.","groupId":"OG000","lowerLimit":"22.0","upperLimit":"NA","value":"NA"},{"comment":"The median OS was not yet reached for either the lenvatinib or the placebo arm (including crossover participants) at data cutoff date.","groupId":"OG001","lowerLimit":"14.3","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"261"},{"groupId":"OG001","value":"131"}],"units":"Participants"}],"description":"Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenvatinib 24 mg, hard capsule, orally, once daily, until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Randomization Phase: Lenvatinib 24 mg"},{"description":"Participants received matching-placebo, hard capsule, orally, once daily until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"Randomization Phase: Placebo"}],"paramType":"MEDIAN","populationDescription":"The full analysis set (Intent-to-Treat Analysis Set) included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}